Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

09/07/2026, 1:00 PM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

08/31/2026, 5:04 AM • GlobeNewswire

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.

08/28/2026, 9:00 AM • GlobeNewswire

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

08/27/2026, 1:00 PM • GlobeNewswire

2 Stocks That Could Capitalize on the GLP-1 Boom

The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.

08/25/2026, 3:18 PM • The Motley Fool

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

08/25/2026, 12:46 PM • GlobeNewswire

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

08/07/2026, 5:56 AM • GlobeNewswire

Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

07/24/2026, 9:30 AM • GlobeNewswire

Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

07/22/2026, 4:49 AM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate

The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.

07/17/2026, 6:44 AM • GlobeNewswire

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

07/17/2026, 5:54 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Global Biochemistry Analyzer Market to Reach $8.18 Billion by 2035 as Diagnostic Testing Demand Accelerates

The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagnostic centers, and research institutions globally.

07/15/2026, 5:24 AM • GlobeNewswire